Stock symbol: TSX: TOS
Outstanding shares: 57,897,451
QUEBEC CITY, May 27 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings using ozone, announces the shipment of the first new 3M(TM) Optreoz(TM) 125-Z sterilizer with TSO3 STERIZONE(R) Technology.
"Today is an important day in TSO3's history", said R.M. (Ric) Rumble, CEO at TSO3. "Today, we are shipping the first of the new 3M(TM) Optreoz(TM) 125-Z sterilizers to our global channel partner 3M(TM). While we have additional shipments planned, all for 3M(TM) training purposes at this time, this first new sterilizer is truly special in that it represents our ability to deliver a validated and fully functional unit meeting 3M(TM) requirements. As at team, we have come a very long way in a very short period of time and I couldn't be more proud of the quality of our work".
In December 2009, TSO3 announced a multi-year global channel partnership with 3M(TM) Infection Prevention Division, for the exclusive supply and distribution of its new sterilizer through 3M's worldwide operations under the 3M(TM) Optreoz(TM) 125-Z brand.
This new sterilizer offers three sterilization cycles in a single unit and is able to quickly and gently sterilize large loads of packaged simple and complex medical devices, ranging from general surgical instruments, to short and long, rigid and flexible endoscopes, including complex multi-channel devices; this product is a unique offering in low-temperature gaseous sterilization. This new sterilizer is approved for sale in Canada and Europe and is currently being reviewed by the US Regulatory Agency.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solution to other low temperature sterilization processes currently being used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: For further information: Caroline Côté, Director, Corporate Communications and Investor Relations, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO3 Inc.